12 September 2018: Infectious diseases, such as hepatitis and Human Papillomavirus (HPV) are caused by microorganisms including bacteria, viruses, and fungi. Infectious disease therapeutics are novel drugs or medicines designed to alleviate the pain of those afflicted with such diseases.
According to the Centers for Disease Control and Prevention (CDC), the cancer survival rate had increased to 62.7% due to introduction of customized medicine. Innovations in gene identification and increased use of electronic devices to document results of clinical trials are expected to spur the development of new drugs.
Novel Drugs to Inhibit Growth of Viruses
Major diseases focused by infectious disease therapeutic manufacturers include HPV, HIV, hepatitis, malaria, Tuberculosis (TB), and influenza. The HIV segment accounted for 45.9% of the overall share in 2016 due to large number of HIV cases. Antiretroviral Therapy (ART) has been used to treat HIV-afflicted people. For instance, Tipranavir by Boehringer Ingelheim acts as protease inhibitor and prevents growth of the virus. In addition, sale of self-testing kits to identify HIV patients can play a huge role in controlling the growth of the disease.
The HIV Self-Testing Africa (STAR) Initiative led by Unitaid aims to diagnose and successfully treat 90 % of HIV patients by 2020. Hepatitis was the second-largest segment in 2016 due to launch of new drugs to treat the disease and new initiatives undertaken to create awareness about them. In addition, successful approval of drugs to treat Hepatitis C Virus (HCV) is expected to drive growth of this segment. Direct-Acting Antivirals (DAA) have displayed a good performance in controlling the growth of HCV.
Market Overview
The infectious disease therapeutics market is anticipated to reach at USD 86.2 billion by 2025, according to a report by Grand View Research, Inc. It is projected to expand at a CAGR of 6.6% over the forecast period (from 2018 to 2025). Reimbursement schemes for consumers, government support for clinical trials, and availability of generic drugs are predicted to augur well for the market growth.
The proposal to push for universal health coverage that provides basic health amenities to poverty-ridden households can provide new growth avenues. Prominent companies in this market include Novartis AG; Janssen Pharmaceutical, Inc.; BioCryst Pharmaceuticals, Inc.; and Boehringer Ingelheim GmbH.
Read more @
No comments:
Post a Comment